Gilead's Q1'26 Earnings Call: Anito-cel poised for December PDUFA decision, three acquisitions near inflection points

Gilead Sciences' [Q1 2026 earnings conference call](https://seekingalpha.com/article/4900864-gilead-sciences-inc-gild-q1-2026-earnings-call-transcript), held on May 7, 2026, with company executives highlighting a dense set of regulatory and clinical catalysts during its Q1 2026 earnings call, with a December 2026 US FDA PDUFA date for BCMA-targeted CAR-T anitocabtagene autoleucel and multiple Trodelvy (sacituzumab govitecan-hziy) readouts in H2 2026 representing key near-term events. The update also drew analyst attention to the absence of disclosed data from a completed Phase II ulcerative colitis trial of emvistagrast, which management said it would address “very soon.” ## **Anito-cel anchors cell therapy strategy ahead of PDUFA** The [April 28, 2026 close ](https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-arcellx-ahead-of-potential-commercial-launch-of-anito-cel)of the Arcellx acquisition brings anitocabtagene autoleucel, a BCMA-directed CAR-T, into Gilead’s pipeline with a US FDA decision expected in December 2026 for fourth-line-plus multiple myeloma. The company said it is preparing for a potential launch in early 2027, contingent on treatment site activation. Gilead is also advancing the therapy into earlier lines through the Phase III iMMagine-3 trial, which has completed enrollment, with study closure expected in Q2 2026. Management indicated additional studies in newly diagnosed patients are in development, while noting that clinical outcomes in earlier treatment settings remain to be established. ## **Trodelvy enters compressed regulatory and data window** TROP2-targeted ADC Trodelvy (sacituzumab govitecan) is approaching multiple regulatory and clinical milestones in H2 2026, including US FDA decisions in first-line metastatic triple-negative breast cancer based on the ASCENT-03 and ASCENT-04 trials. Both studies reported improvements in progression-free survival versus standard of care. Additional Phase III readouts are expected from trials in non-small cell lung cancer and endometrial cancer, creating a concentrated set of events within a single half-year period. An analyst question highlighted competition from datopotamab deruxtecan in triple-negative breast cancer, though Gilead did not provide detailed positioning relative to that asset. ## **ADC expansion adds Tubulis platform** Gilead is expanding its oncology platform through the [pending acquisition of Tubulis](https://allsci.com/news/ma/gilead-sciences-expands-adc-oncology-pipeline-with-usd-5b-acquisition-of-tubulis/), expected to close in Q2 2026. The transaction adds early-stage antibody-drug conjugates, including TUB-040, a NaPi2b-directed candidate currently in Phase I development for ovarian cancer. Management said the platform is intended to complement existing internal capabilities, with future development planned in additional tumor types. Updated clinical data for TUB-040 are expected to be presented in mid-2026. ## **HIV pipeline advances across multiple modalities** The company outlined several upcoming HIV milestones, including an August 2026 US FDA decision for bictegravir plus lenacapavir, a once-daily oral regimen. Phase III updates from the ISLEND-1 and ISLEND-2 studies evaluating once-weekly oral regimens are expected in Q2 2026. Longer-acting approaches remain in earlier development, with a Phase II trial of GS-3242 in combination with lenacapavir planned to begin in H2 2026. Management indicated that development timelines for extended-interval regimens remain subject to ongoing clinical evaluation. ## **Emvistagrast non-disclosure draws analyst focus** The most notable point of analyst scrutiny was the lack of data disclosure from the Phase II ulcerative colitis trial of emvistagrast, an oral alpha-4 beta-7 inhibitor. The study has been marked as completed, but Gilead did not provide any efficacy or safety data during the call. In response to analyst questions, management said the data are under review and that an update would be provided in the near term, without specifying timing. The absence of detail around a completed study represented the primary area of uncertainty highlighted during the earnings discussion. *** This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: [https://allsci.com/news/](https://allsci.com/news/) --- Spot something wrong? [Report an issue with this article](https://newsgen-prod.reframedata.com/feedback/anito-cel-pdufa-decision-gileads-poised-for)